[1] |
BUONO J L, CARSON R T, FLORES N M. Health-related quality of life,work productivity,and indirect costs among patients with irritable bowel syndrome with diarrhea[J]. Health Qual Life Outcomes, 2017, 15(1):35. DOI: 10.1186/s12955-017-0611-2.
|
[2] |
FRÄNDEMARK Å, TÖRNBLOM H, JAKOBSSON S,et al. Work productivity and activity impairment in irritable bowel syndrome (IBS):a multifaceted problem[J]. Am J Gastroenterol, 2018, 113:1540-1549. DOI: 10.1038/s41395-018-0262-x.
|
[3] |
CAMILLERI M. Diagnosis and treatment of irritable bowel syndrome:a review[J]. JAMA, 2021, 325(9):865-877. DOI: 10.1001/jama.2020.22532.
|
[4] |
ZHANG F, XIANG W, LI C Y,et al. Economic burden of irritable bowel syndrome in China[J]. World J Gastroenterol, 2016, 22(47):10450-10460. DOI: 10.3748/wjg.v22.i47.10450.
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
FORD A C, LACY B E, TALLEY N J. Irritable bowel syndrome[J]. N Engl J Med, 2017, 376(26):2566-2578. DOI: 10.1056/NEJMra1607547.
|
[10] |
STASI C, BELLINI M, BASSOTTI G,et al. Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome[J]. Tech Coloproctol, 2014, 18(7):613-621. DOI: 10.1007/s10151-013-1106-8.
|
[11] |
唐吟菡,许树长,吴萍. 食物敏感与肠易激综合征研究进展[J]. 世界华人消化杂志,2012,20(5):35-39.
|
[12] |
|
[13] |
FORD A C, SUARES N C. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation:systematic review and meta-analysis[J]. Gut, 2011, 60(2):209-218. DOI: 10.1136/gut.2010.227132.
|
[14] |
CHAPMAN R W, STANGHELLINI V, GERAINT M,et al. Randomized clinical trial:macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome[J]. Am J Gastroenterol, 2013, 108(9):1508-1515. DOI: 10.1038/ajg.2013.197.
|
[15] |
FORD A C, LACY B E, HARRIS L A,et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome:an updated systematic review and meta-analysis[J]. Am J Gastroenterol, 2019, 114(1):21-39. DOI: 10.1038/s41395-018-0222-5.
|
[16] |
HOUGHTON L A, FOSTER J M, WHORWELL P J. Alosetron,a 5-HT3 receptor antagonist,delays colonic transit in patients with irritable bowel syndrome and healthy volunteers[J]. Aliment Pharmacol Ther, 2000, 14(6):775-782. DOI: 10.1046/j.1365-2036.2000.00762.x.
|
[17] |
MIN Y W, RHEE P L. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)[J]. Therap Adv Gastroenterol, 2015, 8(3):136-142. DOI: 10.1177/1756283X15572580.
|
[18] |
QI Q Q, ZHANG Y, CHEN F X,et al. Ramosetron for the treatment of irritable bowel syndrome with diarrhea:a systematic review and meta-analysis of randomized controlled trials[J]. BMC Gastroenterol, 2018, 18(1):5. DOI: 10.1186/s12876-017-0734-2.
|
[19] |
FARKOUH A, RIEDL T, GOTTARDI R,et al. Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs:a review of the literature[J]. Adv Ther, 2020, 37(2):644-655. DOI: 10.1007/s12325-019-01201-3.
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
唐丽明,宋宁,袁红霞. 中药复方治疗肠易激综合征的实验研究进展[J]. 中国实验方剂学杂志,2013,19(19):355-360.
|
[25] |
税杰. 基于5-HT信号通路研究痛泻要方白芍防风组分缓解IBS-D内脏高敏的机制[D]. 成都:成都中医药大学,2017.
|
[26] |
王微,张北华,王凤云,等. 肠安合剂对腹泻型肠易激综合征大鼠血清中5-羟色胺表达的影响[J]. 中华中医药杂志,2015,30(11):3905-3909.
|
[27] |
张北华,王微,王凤云,等. 痛泻要方干预腹泻型肠易激综合征肝郁脾虚证模型大鼠的效应评价[J]. 中华中医药杂志,2018,33(10):4341-4346.
|
[28] |
|
[29] |
|
[30] |
郑超伟,李桂贤,李敏,等. 加味柴芍六君颗粒对便秘型肠易激综合征模型大鼠结肠组织5-HT的影响[J]. 实用中医药杂志,2019,35(4):386-388.
|
[31] |
陈芳,施琳琳,王峻,等. 理气通便合剂对便秘型肠易激综合征模型大鼠结肠、下丘脑组织5-HT、VIP的影响[J]. 浙江中西医结合杂志,2021,31(2):107-110.
|
[32] |
|
[33] |
|
[34] |
刘芳,魏先鹏,唐学贵.四君子汤加减对肠易激综合征患者5-HT3受体、5-HT4受体及炎症指标的影响[J]. 中药材,2021. [Epub ahead of print].
|
[35] |
|
[36] |
|
[37] |
|
[38] |
|
[39] |
裴丽霞. 基于5-HT信号系统探讨电针治疗便秘型肠易激综合征的机制[D]. 南京:南京中医药大学,2017.
|
[40] |
|
[41] |
刘薇. 穴位埋线法治疗便秘型肠易激综合征的临床与实验研究[D]. 北京:北京中医药大学,2019.
|
[42] |
|
[43] |
|
[44] |
|
[45] |
|
[46] |
|
[47] |
|
[48] |
|
[49] |
林燕. 肠易激综合征不同中医证型与5-羟色胺的相关性研究[C]//中国中西医结合学会消化系统疾病专业委员会.第二十二届全国中西医结合消化系统疾病学术会议暨消化疾病诊治进展学习班论文汇编. 中国中西医结合学会消化系统疾病专业委员会:中国中西医结合学会,2010:430-432.
|